Kanabidiol

Kanabidiol
IUPAC ime
	2-[(1R,6R)-6-izopropenil-3-metilcikloheks-2-en-1-il]-5-pentilbenzen-1,3-diol
Klinički podaci
Prodajno ime	Epidiolex
Drugs.com	Internacionalno ime leka
Pravni status
Pravni status	AU: S4 (Prescription only) ; CA: Plan II ; UK: Prehrambeni suplement ili POM ; US: Plan I ;
Farmakokinetički podaci
Bioraspoloživost	13–19% (oralno), 11–45% (prosek 31%; inhalaciono)
Poluvreme eliminacije	9 h
Identifikatori
CAS broj	13956-29-1
ATC kod	None
PubChem	CID 644019
IUPHAR/BPS	4150
ChemSpider	24593618
UNII	19GBJ60SN5
ChEBI	CHEBI:69478
Hemijski podaci
Formula	C21H30O2
Molarna masa	314.4636
	SMILES Oc1c(c(O)cc(c1)CCCCC)[C@@H]2\C=C(/CC[C@H]2\C(=C)C)C; ;
	InChI InChI=1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h9,12-13,17-18,22-23H,2,5-8,10-11H2,1,3-4H3/t17-,18+/m0/s1 ; Key:ZTGXAWYVTLUPDT-ZWKOTPCHSA-N ;
Fizički podaci
Tačka topljenja	66 °C (151 °F)
Tačka ključanja	180 °C (356 °F) ; (opseg: 160–180 °C)

Kanabidiol (CBD) je kanabinoid prisutan u kanabisu. On je glavni sastojak biljke, koji sačinjava do 40% njenog ekstrakta.^[5]

On pokazuje sedativno dejstvo u testovima na životinjama.^[6] Neka istraživanja, međutim, indiciraju da CBD može da poveća budnost.^[7] On može da umanji brzinu uklanjanja THC-a iz tela, verovatno putem ometanja metabolizma THC-a u jetri.

Pokazano je da omanjuje konvulzije, inflamaciju, anksioznost, i mučninu, kao i da inhibira rast ćelija kancera.^[8] Nedavne studije su pokazale da je kanabidiol efektivan kao atipični antipsihotik u tretmanu šizofrenije.^[9] Ispitivanja su takođe pokazala da olakšava simptome distonije.^[10]^[11]

Novembera 2007. je objavljeno da CBD redukuje rast agresivnih ljudskih ćelija raka dojke in vitro i da umanjuje njihovu invazivnost.

Vidi još[уреди | уреди извор]

Reference[уреди | уреди извор]

^ DEA News Release, DEA Eases Requirements for FDA Approved Clinical Trials on Cannabidiol (December 23, 2015) ("CBD is a Schedule I controlled substance as defined under the CSA."), http://www.dea.gov/divisions/hq/2015/hq122315.shtml; Joseph T. Rannazzisi Deputy Assistant Administrator Drug Enforcement Administration Before the Caucus on International Narcotics Control, United States Senate, at 2 (June 24, 2015) (CBD is a Schedule I drug.); see also Frank Robison, Elvira Strehle-Henson, Cannabis Laws and Research at Colorado Institutions of Higher Education, COLO. LAW., OCTOBER 2015, AT 73, 76 ("[T]the DEA's position on CBD is clear—it is a Schedule I substance.").
↑ ^2,0 ^2,1 Mechoulam R, Parker LA, Gallily R (2002). „Cannabidiol: an overview of some pharmacological aspects”. J Clin Pharmacol (Review). 42 (11 Suppl): 11S—19S. PMID 12412831. doi:10.1177/0091270002238789.
^ Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G (2009). „Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders”. Phytother Res (Review). 23 (5): 597—602. PMID 18844286. doi:10.1002/ptr.2625.
^ McPartland JM, Russo EB (2001). „Cannabis and cannabis extracts: greater than the sum of their parts?” (PDF). Journal of Cannabis Therapeutics. 1 (3/4): 103—132. doi:10.1300/J175v01n03_08.
^ Grlić, Ljubiša (1962). „A comparative study on some chemical and biological characteristics of various samples of cannabis resin”. Bulletin on Narcotics. United Nations Office on Drugs and Crime (3): 37—46.
^ Pickens JT (1981). „Sedative activity of cannabis in relation to its delta'-trans-tetrahydrocannabinol and cannabidiol content”. British Journal of Pharmacology. 72 (4): 649—56. PMC 2071638 . PMID 6269680.
^ Nicholson, AN; C Turner; et al. (2004). „Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults”. J Clin Psychopharmacol. 24 (3): 305—13. ISSN 0271-0749. PMID 15118485. doi:10.1097/01.jcp.0000125688.05091.8f. Архивирано из оригинала (fee required) на датум 18. 07. 2011. Приступљено 3. 5. 2007.
^ Mechoulam, R.; M. Peters; Murillo-Rodriguez (21. 8. 2007). „Cannabidiol - recent advances”. Chemistry & Biodiversity. 4 (8): 1678—1692. PMID 17712814. doi:10.1002/cbdv.200790147. ^{[мртва веза]}
^ Zuardi, A.W; J.A.S. Crippa; et al. (2006). „Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug” (PDF). Brazilian Journal of Medical and Biological Research. 39 (4): 421—429. PMID 16612464. doi:10.1590/S0100-879X2006000400001.
^ Consroe, P.; Sandyk, R.; Snider, S. R. (1986). „Open label evaluation of cannabidiol in dystonic movement disorders”. The International journal of neuroscience. 30 (4): 277—282. PMID 3793381. doi:10.3109/00207458608985678.
^ Snider, Stuart R.; Consroe, Paul (1985). „Beneficial and Adverse Effects of Cannabidiol in a Parkinson Patient with Sinemet-Induced Dystonic Dyskinesia”. Neurology (Suppl 1): 201.

Spoljašnje veze[уреди | уреди извор]

Erowid Compounds found in Cannabis sativa

[1] DEA News Release, DEA Eases Requirements for FDA Approved Clinical Trials on Cannabidiol (December 23, 2015) ("CBD is a Schedule I controlled substance as defined under the CSA."), http://www.dea.gov/divisions/hq/2015/hq122315.shtml; Joseph T. Rannazzisi Deputy Assistant Administrator Drug Enforcement Administration Before the Caucus on International Narcotics Control, United States Senate, at 2 (June 24, 2015) (CBD is a Schedule I drug.); see also Frank Robison, Elvira Strehle-Henson, Cannabis Laws and Research at Colorado Institutions of Higher Education, COLO. LAW., OCTOBER 2015, AT 73, 76 ("[T]the DEA's position on CBD is clear—it is a Schedule I substance.").

[Mechoulam2002-2] 2,0 ^2,1 Mechoulam R, Parker LA, Gallily R (2002). „Cannabidiol: an overview of some pharmacological aspects”. J Clin Pharmacol (Review). 42 (11 Suppl): 11S—19S. PMID 12412831. doi:10.1177/0091270002238789.

[Scuderi2009-3] Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G (2009). „Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders”. Phytother Res (Review). 23 (5): 597—602. PMID 18844286. doi:10.1002/ptr.2625.

[4] McPartland JM, Russo EB (2001). „Cannabis and cannabis extracts: greater than the sum of their parts?” (PDF). Journal of Cannabis Therapeutics. 1 (3/4): 103—132. doi:10.1300/J175v01n03_08.

[Grlic_1962-5] Grlić, Ljubiša (1962). „A comparative study on some chemical and biological characteristics of various samples of cannabis resin”. Bulletin on Narcotics. United Nations Office on Drugs and Crime (3): 37—46.

[pmid6269680-6] Pickens JT (1981). „Sedative activity of cannabis in relation to its delta'-trans-tetrahydrocannabinol and cannabidiol content”. British Journal of Pharmacology. 72 (4): 649—56. PMC 2071638 . PMID 6269680.

[7] Nicholson, AN; C Turner; et al. (2004). „Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults”. J Clin Psychopharmacol. 24 (3): 305—13. ISSN 0271-0749. PMID 15118485. doi:10.1097/01.jcp.0000125688.05091.8f. Архивирано из оригинала (fee required) на датум 18. 07. 2011. Приступљено 3. 5. 2007.

[recentadvances-8] Mechoulam, R.; M. Peters; Murillo-Rodriguez (21. 8. 2007). „Cannabidiol - recent advances”. Chemistry & Biodiversity. 4 (8): 1678—1692. PMID 17712814. doi:10.1002/cbdv.200790147. ^{[мртва веза]}

[braz-9] Zuardi, A.W; J.A.S. Crippa; et al. (2006). „Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug” (PDF). Brazilian Journal of Medical and Biological Research. 39 (4): 421—429. PMID 16612464. doi:10.1590/S0100-879X2006000400001.

[pmid3793381-10] Consroe, P.; Sandyk, R.; Snider, S. R. (1986). „Open label evaluation of cannabidiol in dystonic movement disorders”. The International journal of neuroscience. 30 (4): 277—282. PMID 3793381. doi:10.3109/00207458608985678.

[Snider1985-11] Snider, Stuart R.; Consroe, Paul (1985). „Beneficial and Adverse Effects of Cannabidiol in a Parkinson Patient with Sinemet-Induced Dystonic Dyskinesia”. Neurology (Suppl 1): 201.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

Kanabidiol

Vidi još[уреди | уреди извор]

Reference[уреди | уреди извор]

Spoljašnje veze[уреди | уреди извор]

Мени за навигацију

Претрага